We are delighted to share with you the sixth and final edition of the EUCAN Cluster Newsletter. The EUCAN cluster is made up of the six projects that were funded under the Horizon 2020 call SC1-BHC-05-2018 (CINECA, EUCANCan, EUCAN-Connect, euCanSHare, iReceptor Plus, ReCoDID).

In case you missed the previous edition, published in September 2022, you can view it here.

The current newsletter includes two items on activities of the EUCANCan consortium:

• Introducing the EUCANCan portal
  Researchers and medical professionals often find themselves in a situation where they wish to share or explore data located in different physical locations in a safe and secure way. Responding to this situation, one aim of EUCANCan is to implement a cultural, technological and legal integrated framework across Europe and Canada that enables and facilitates the efficient sharing of cancer genomic and clinical data. To this end, the consortium has developed the EUCANCan Portal, a federated network of interoperable nodes, which allows users to view and search for data files in different locations. Read more »

• EUCANCan workshop
  The EUCANCan project organized an online workshop on 24 May 2023 to discuss what would be needed to bridge the gap between clinical practice and bioinformatics research to allow for joining forces and make this ‘stone soup’. In difficult-to-solve patient cases, especially in rare diseases, but also in cancer, clinicians across the country or even the world are already being consulted and patient information is being shared. What can we learn from how is currently shared data in clinical practice? In bioinformatics, tools are being developed and new insights into cancer and other diseases are gained based on patient data. However, how do we ensure that the results get used in clinical practice and do not linger for eternity in the theoretical world? How do we compete with well-established methods from, for example, the field of pathology? When patient data is shared with the world of research, how do we ensure both sides benefit from it? Read more »